source
- Merck's remigromig meets visual acuity goal in diabetic macular edema trial, safety signals notedMerck announced that its experimental eye drug remigromig achieved non‑inferiority to Roche’s Lucentis in a late‑stage trial for diabetic macular edema. The trial, called Brunello, measured visual…
- Roche signs discovery partnerships with Atavistik Bio and Earendil LabsRoche announced new collaborations with the drug discovery companies Atavistik Bio and Earendil Labs to develop early-stage candidates. The agreements continue a recent wave of dealmaking by the S…